<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://drugfacts.org.uk/index.php?action=history&amp;feed=atom&amp;title=Naxolone</id>
	<title>Naxolone - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://drugfacts.org.uk/index.php?action=history&amp;feed=atom&amp;title=Naxolone"/>
	<link rel="alternate" type="text/html" href="https://drugfacts.org.uk/index.php?title=Naxolone&amp;action=history"/>
	<updated>2026-04-24T13:25:59Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.31.1</generator>
	<entry>
		<id>https://drugfacts.org.uk/index.php?title=Naxolone&amp;diff=611&amp;oldid=prev</id>
		<title>Sharon: /* Harm reduction */</title>
		<link rel="alternate" type="text/html" href="https://drugfacts.org.uk/index.php?title=Naxolone&amp;diff=611&amp;oldid=prev"/>
		<updated>2017-05-20T11:56:07Z</updated>

		<summary type="html">&lt;p&gt;‎&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;Harm reduction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;Revision as of 11:56, 20 May 2017&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l169&quot; &gt;Line 169:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 169:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Some specialist services do an overdose prevention training protocol that includes naloxone. Find out if you can get you or a family member involved if there is a risk of an opiate overdose.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Some specialist services do an overdose prevention training protocol that includes naloxone. Find out if you can get you or a family member involved if there is a risk of an opiate overdose.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Some overdoses are the result of mixing opioids and benzos, resulting in acute respiratory depression, where this is the case a benzodiazepine antagonist ([[&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Flumazanil&lt;/del&gt;]]) would be indicated.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Some overdoses are the result of mixing opioids and benzos, resulting in acute respiratory depression, where this is the case a benzodiazepine antagonist ([[&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;Flumazenil&lt;/ins&gt;]]) would be indicated.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In many cases where people come round from an emergency Narcan shot, they will be in withdrawal. It is wise to exercise some caution before trying to dispel the condition with a normal dose of opiate. Narcan is active for about 45+ minutes in the body. This means that if you give someone Narcan to reverse an opioid overdose, the Narcan may wear off before the effects of the opioids wear off and to use on top of this can be very dangerous. If the Narcan is still active at the receptor the opiate will not be felt, causing frustration and perhaps leading to the situation outlined above by the time the user has sorted out the next 'hit' &amp;lt;ref name=&amp;quot;1177a&amp;quot;/&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;&amp;#160;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In many cases where people come round from an emergency Narcan shot, they will be in withdrawal. It is wise to exercise some caution before trying to dispel the condition with a normal dose of opiate. Narcan is active for about 45+ minutes in the body. This means that if you give someone Narcan to reverse an opioid overdose, the Narcan may wear off before the effects of the opioids wear off and to use on top of this can be very dangerous. If the Narcan is still active at the receptor the opiate will not be felt, causing frustration and perhaps leading to the situation outlined above by the time the user has sorted out the next 'hit' &amp;lt;ref name=&amp;quot;1177a&amp;quot;/&amp;gt;.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Sharon</name></author>
		
	</entry>
	<entry>
		<id>https://drugfacts.org.uk/index.php?title=Naxolone&amp;diff=608&amp;oldid=prev</id>
		<title>Sharon: Created page with &quot;== Also known as ==  Narcan, nalone, evzio  == Classification ==  Opioid, opiate antagonist Category:Opioids Category:Opiate antagonists  == Overview ==  Naloxone is a...&quot;</title>
		<link rel="alternate" type="text/html" href="https://drugfacts.org.uk/index.php?title=Naxolone&amp;diff=608&amp;oldid=prev"/>
		<updated>2017-05-20T11:53:15Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;== Also known as ==  Narcan, nalone, evzio  == Classification ==  Opioid, opiate antagonist &lt;a href=&quot;/index.php?title=Category:Opioids&quot; title=&quot;Category:Opioids&quot;&gt;Category:Opioids&lt;/a&gt; &lt;a href=&quot;/index.php?title=Category:Opiate_antagonists&amp;amp;action=edit&amp;amp;redlink=1&quot; class=&quot;new&quot; title=&quot;Category:Opiate antagonists (page does not exist)&quot;&gt;Category:Opiate antagonists&lt;/a&gt;  == Overview ==  Naloxone is a...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;== Also known as ==&lt;br /&gt;
&lt;br /&gt;
Narcan, nalone, evzio&lt;br /&gt;
&lt;br /&gt;
== Classification ==&lt;br /&gt;
&lt;br /&gt;
Opioid, opiate antagonist&lt;br /&gt;
[[Category:Opioids]] [[Category:Opiate antagonists]]&lt;br /&gt;
&lt;br /&gt;
== Overview ==&lt;br /&gt;
&lt;br /&gt;
Naloxone is a drug that reverses the effects of opioids among dependent individuals &amp;lt;ref name=&amp;quot;1177a&amp;quot;&amp;gt;'''Naloxone''', 2017, http://www.release.org.uk/drugs/naloxone&amp;lt;/ref&amp;gt;. Naloxone blocks or reverses the effects of opioid medication, including extreme drowsiness, slowed breathing, or loss of consciousness.&lt;br /&gt;
&lt;br /&gt;
Naloxone is used to treat a narcotic overdose in an emergency situation. This medicine should not be used in place of emergency medical care for an overdose &amp;lt;ref name=&amp;quot;1181a&amp;quot;&amp;gt;'''Naloxone''', 2017, https://www.drugs.com/mtm/naloxone.html&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.&lt;br /&gt;
&lt;br /&gt;
For the complete or partial reversal of narcotic depression, including [[respiratory depression]], induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. It is also indicated for the diagnosis of suspected acute opioid overdose. It may also be used as an adjunctive agent to increase blood pressure in the management of septic shock &amp;lt;ref name=&amp;quot;1183a&amp;quot;&amp;gt;'''Naloxone''', 2017, https://www.drugbank.ca/drugs/DB01183&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Medical usage ==&lt;br /&gt;
&lt;br /&gt;
Naloxone is specifically used to counteract life-threatening depression of the [[central nervous system]] and respiratory system. It is not to be confused with [[Naltrexone]], an opioid receptor antagonist, used for dependence treatment rather than emergency overdose treatment &amp;lt;ref name=&amp;quot;1178a&amp;quot;&amp;gt;'''Naloxone''', 2012, http://www.dan247.org.uk/Drug_Naloxone.asp&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== What does it look like? ==&lt;br /&gt;
&lt;br /&gt;
Colourless liquid, usually in a vial or within an auto-injector &amp;lt;ref name=&amp;quot;1177a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Source ==&lt;br /&gt;
&lt;br /&gt;
Naloxone is derived from Thebaine. Thebaine (paramorphine) is a naturally occurring chemical of Opium, but has stimulatory rather than depressant effects &amp;lt;ref name=&amp;quot;1178a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Dosage ==&lt;br /&gt;
&lt;br /&gt;
=== Therapeutic ===&lt;br /&gt;
&lt;br /&gt;
* intramuscular - commonly -	0.4 - 2 mg,&lt;br /&gt;
* insufflated - commonly - 	1 - 4 mg &amp;lt;ref name=&amp;quot;1179a&amp;quot;&amp;gt;'''Naloxone''', 2017, https://psychonautwiki.org/wiki/Naloxone&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== What are the different forms? ==&lt;br /&gt;
&lt;br /&gt;
* injection,&lt;br /&gt;
* autoinjectable,&lt;br /&gt;
* nasal spray.&lt;br /&gt;
&lt;br /&gt;
== How long do its effects last? ==&lt;br /&gt;
&lt;br /&gt;
=== Onset of effects ===&lt;br /&gt;
&lt;br /&gt;
* intramuscular - 0 - 5 minutes,&lt;br /&gt;
* insufflated - 0 - 10 minutes &amp;lt;ref name=&amp;quot;1179a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Duration of effects ===&lt;br /&gt;
&lt;br /&gt;
* intramuscular - 30 - 60 minutes,&lt;br /&gt;
* insufflated - 30 - 60 minutes &amp;lt;ref name=&amp;quot;1179a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Pharmacology ==&lt;br /&gt;
&lt;br /&gt;
Naloxone has an extremely high affinity for μ-opioid receptors in the [[central nervous system]]. Naloxone is a μ-opioid receptor competitive antagonist, and its rapid blockade of those receptors often produces rapid onset of withdrawal symptoms. Naloxone also has an antagonist action, though with a lower affinity, at k and δ-opioid receptors.&lt;br /&gt;
&lt;br /&gt;
There have been community Naloxone distribution via peer group networks in the UK for some years. There are currently plans to introduce a more family/relative friendly buccal spray, as some families and carers have reported time consuming difficulties in locating and using Narcan - filled syringes.&lt;br /&gt;
&lt;br /&gt;
Naloxone is used as a secondary chemical in the drug Suboxone. Suboxone and Subutex are NICE licenced treatments for opioid dependence in the UK. Suboxone contains four parts buprenorphine and one part naloxone, while Subutex contains only buprenorphine. Naloxone was added to Suboxone in an effort to dissuade patients from crushing and snorting or injecting the tablets (sub-linguals).&lt;br /&gt;
&lt;br /&gt;
Like Naltrexone, Naloxone has been shown to block the action of pain-lowering endorphins/dynorphins which the body produces naturally. The reason for this is that these endorphins operate on the same opioid receptors that naloxone blocks, hence the low mood and irritability that often affects people on Nalorex tablets &amp;lt;ref name=&amp;quot;1177a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
Naloxone acts as a potent μ-opioid receptor inverse agonist. Because of its high affinity for the μ-opioid receptor, it knocks other ligands out of the receptor. Naloxone also has a lower affinity as an antagonism at the κ-opioid and δ-opioid receptors. If naloxone is administered without previous administration of opioids, it has few biological effects, notably a lower pain threshold. Naloxone has two isomers, (+)naloxone and (-)naloxone, with the latter being active. The liver metabolises naloxone. It has very low oral bioavailability which is why it is administered intravenously, intramuscularly or intranasally. Small amounts of naloxone are often added to opioids like buprenorphine and pentazocine to prevent abuse. Naloxone has been noted to block a [[placebo]] based [[analgesic]] effect. For example, if an individual has been administered something that they were told was morphine and had a [[analgesic]] response to it, naloxone will block that response &amp;lt;ref name=&amp;quot;1180a&amp;quot;&amp;gt;Sauro, M. D. and Greenberg, R. P., '''Endogenous opiates and the placebo effect''', ''Journal of Psychosomatic Research'', 2005, 58, 2, 115-120, http://dx.doi.org/10.1016/j.jpsychores.2004.07.001, http://www.jpsychores.com/article/S0022-3999(04)00515-X/abstract&amp;lt;/ref&amp;gt;, &amp;lt;ref name=&amp;quot;1179a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Pharmacodynamics ===&lt;br /&gt;
&lt;br /&gt;
Naloxone is an opiate antagonist and prevents or reverses the effects of opioids including [[respiratory depression]], [[sedation]] and [[hypotension]]. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine. Naloxone is an essentially pure narcotic antagonist, i.e., it does not possess the &amp;quot;agonistic&amp;quot; or morphine-like properties characteristic of other narcotic antagonists; naloxone does not produce [[respiratory depression]], psychotomimetic effects or pupillary constriction. In the absence of narcotics or agonistic effects of other narcotic antagonists, it exhibits essentially no pharmacologic activity. When given intravenously, the onset of action is apparent within 2 minutes. The onset of action is slower if given subcutaneously or intramuscularly. The duration of action also differs between sites of injection and dose &amp;lt;ref name=&amp;quot;1183a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Route of administration ===&lt;br /&gt;
&lt;br /&gt;
* injection,&lt;br /&gt;
* autoinjectable,&lt;br /&gt;
* nasal spray.&lt;br /&gt;
&lt;br /&gt;
=== Absorption ===&lt;br /&gt;
&lt;br /&gt;
Well absorbed following intramuscular injection &amp;lt;ref name=&amp;quot;1183a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Volume of distribution ===&lt;br /&gt;
&lt;br /&gt;
Following parenteral administration naloxone hydrochloride is rapidly distributed in the body. Naloxone is also very lipophillic and easily crosses the blood-brain-barrier. It can also cross the placenta &amp;lt;ref name=&amp;quot;1183a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Metabolism ===&lt;br /&gt;
&lt;br /&gt;
Naloxone is hepatically metabolised and primarily undergoes glucuronidation to form naloxone-3-glucuronide &amp;lt;ref name=&amp;quot;1183a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Half-life ===&lt;br /&gt;
&lt;br /&gt;
Adults = 30 - 81 minutes &amp;lt;ref name=&amp;quot;1183a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Elimination ===&lt;br /&gt;
&lt;br /&gt;
Urine (25% - 40% is excreted as metabolites within 6 hours) &amp;lt;ref name=&amp;quot;1183a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Lethal dosage ===&lt;br /&gt;
&lt;br /&gt;
[[LD50]] [[IV]] administration - mouse = 150 ± 5 mg/kg, [[LD50]] [[IV]] administration - rat = 109 ± 4 mg/kg &amp;lt;ref name=&amp;quot;1183a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Mechanism of action ===&lt;br /&gt;
&lt;br /&gt;
While the mechanism of action of naloxone is not fully understood, the preponderance of evidence suggests that naloxone antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Recently, naloxone has been shown to bind all three opioid receptors (mu, kappa and gamma) but the strongest binding is to the mu receptor &amp;lt;ref name=&amp;quot;1183a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Mode of use ==&lt;br /&gt;
&lt;br /&gt;
* injected - Naloxone may be given by injection into a vein, muscle or under the skin, or via a drip into a vein &amp;lt;ref name=&amp;quot;1177a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Effects ==&lt;br /&gt;
&lt;br /&gt;
=== Physical effects ===&lt;br /&gt;
&lt;br /&gt;
* sedation &amp;lt;ref name=&amp;quot;1179a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Cognitive effects ===&lt;br /&gt;
&lt;br /&gt;
* emotionality suppression &amp;lt;ref name=&amp;quot;1179a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Major effects ===&lt;br /&gt;
&lt;br /&gt;
==== Incidence not known ====&lt;br /&gt;
&lt;br /&gt;
* abdominal or stomach cramps,&lt;br /&gt;
* body aches,&lt;br /&gt;
* convulsions,&lt;br /&gt;
* diarrhoea,&lt;br /&gt;
* difficult or troubled breathing,&lt;br /&gt;
* excessive crying,&lt;br /&gt;
* fast, pounding, or irregular heartbeat or pulse,&lt;br /&gt;
* fever,&lt;br /&gt;
* goose-bumps,&lt;br /&gt;
* increased blood pressure,&lt;br /&gt;
* increased or excessive unconscious or jerking movements,&lt;br /&gt;
* irregular, fast or slow, or shallow breathing,&lt;br /&gt;
* irritability,&lt;br /&gt;
* nausea,&lt;br /&gt;
* vomiting,&lt;br /&gt;
* nervousness,&lt;br /&gt;
* cyanosis,&lt;br /&gt;
* restlessness,&lt;br /&gt;
* runny nose,&lt;br /&gt;
* shivering,&lt;br /&gt;
* sneezing,&lt;br /&gt;
* sweating,&lt;br /&gt;
* trembling,&lt;br /&gt;
* weakness,&lt;br /&gt;
* yawning &amp;lt;ref name=&amp;quot;1181a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Side-effects ===&lt;br /&gt;
&lt;br /&gt;
* nausea,&lt;br /&gt;
* vomiting,&lt;br /&gt;
* sweating,&lt;br /&gt;
* increased heart rate,&lt;br /&gt;
* hyperventilation,&lt;br /&gt;
* increased blood pressure,&lt;br /&gt;
* reversal of pain relief if larger than necessary doses are given,&lt;br /&gt;
* irregular heart beat,&lt;br /&gt;
* low blood pressure &amp;lt;ref name=&amp;quot;1178a&amp;quot;/&amp;gt;,&lt;br /&gt;
* chest tightness,&lt;br /&gt;
* intense rash with itching,&lt;br /&gt;
* seizures,&lt;br /&gt;
* acute allergic reaction with swelling of the face, lips, tongue and throat &amp;lt;ref name=&amp;quot;0411a&amp;quot;&amp;gt;Upfal, J., '''The Australian Drug Guide''', 2006, Black Inc., Melbourne&amp;lt;/ref&amp;gt;, &amp;lt;ref name=&amp;quot;1182a&amp;quot;&amp;gt;'''Naloxone''', 2017, http://adf.org.au/drug-facts/naloxone/&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Harm reduction ==&lt;br /&gt;
&lt;br /&gt;
Some specialist services do an overdose prevention training protocol that includes naloxone. Find out if you can get you or a family member involved if there is a risk of an opiate overdose.&lt;br /&gt;
&lt;br /&gt;
Some overdoses are the result of mixing opioids and benzos, resulting in acute respiratory depression, where this is the case a benzodiazepine antagonist ([[Flumazanil]]) would be indicated.&lt;br /&gt;
&lt;br /&gt;
In many cases where people come round from an emergency Narcan shot, they will be in withdrawal. It is wise to exercise some caution before trying to dispel the condition with a normal dose of opiate. Narcan is active for about 45+ minutes in the body. This means that if you give someone Narcan to reverse an opioid overdose, the Narcan may wear off before the effects of the opioids wear off and to use on top of this can be very dangerous. If the Narcan is still active at the receptor the opiate will not be felt, causing frustration and perhaps leading to the situation outlined above by the time the user has sorted out the next 'hit' &amp;lt;ref name=&amp;quot;1177a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== History ==&lt;br /&gt;
&lt;br /&gt;
Naloxone was first synthesised in 1960 by Jack Fishman, an assistant at the Sloan Kettering Institute for Cancer Research, New York and developed by Harold Blumberg, a director at Endo Laboratories, NY. A British patent for naloxone was applied for by the Japanese company Sankyo Pharmaceuticals in March 1962 and issued in October 1963 &amp;lt;ref name=&amp;quot;1177a&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span id=&amp;quot;BackToTop&amp;quot;&amp;gt;&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;div class=&amp;quot;noprint&amp;quot; style=&amp;quot;background-color:#fc3; color:#d33; position:fixed; bottom:2%; left:0.25%; padding:0; margin:0;&amp;quot;&amp;gt;&lt;br /&gt;
[[#top| '''Back to the Top''' ]]&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;br /&gt;
&amp;lt;span id=&amp;quot;BackToTop&amp;quot;&amp;gt;&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;div class=&amp;quot;noprint&amp;quot; style=&amp;quot;background-color:#fc3; color:#d33; position:fixed; bottom:2%; right:0.25%; padding:0; margin:0;&amp;quot;&amp;gt;&lt;br /&gt;
[[#top| '''Back to the Top''' ]]&lt;br /&gt;
&amp;lt;/div&amp;gt;&lt;/div&gt;</summary>
		<author><name>Sharon</name></author>
		
	</entry>
</feed>